Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 21, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Soleno Therapeutics, Inc. (SLNO) has a Wall Street consensus price target of $105.20, based on estimates from 11 covering analysts. With the stock currently trading at $39.07, this represents a potential upside of +169.3%. The company has a market capitalization of $145692.
Analyst price targets range from a low of $60.00 to a high of $125.00, representing a 62% spread in expectations. The median target of $114.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SLNO trades at a trailing P/E of 100.2x and forward P/E of 9.3x. Analysts expect EPS to grow +994.9% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SLNO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for SLNO is $105.2, representing 169.3% upside from the current price of $39.07. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SLNO has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $105.2 implies 169.3% upside from current levels.
With a forward P/E of 9.2803x, SLNO trades at a relatively low valuation. The consensus target of $105.2 implies 169.3% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $125 for SLNO, while the most conservative target is $60. The consensus of $105.2 represents the median expectation. These targets typically reflect 12-month expectations.
SLNO is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SLNO stock forecast based on 11 Wall Street analysts shows a consensus price target of $105.2, with estimates ranging from $60 (bear case) to $125 (bull case). The median consensus rating is "Buy".
SLNO trades at a forward P/E ratio of 9.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 100.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on SLNO, with a "Buy" consensus rating and $105.2 price target (169.3% upside). 11 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SLNO analyst price targets range from $60 to $125, a 62% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $105.2 consensus represents the middle ground.